MULTIPLE BIOMARKER PANELS TO STRATIFY DISEASE SEVERITY AND MONITOR TREATMENT OF DEPRESSION
Materials and Methods for identifying and measuring pharmacodynamic biomarkers of neuropsychiatric disease (e.g., major depressive disorder), stratifying disease severity, and monitoring a subject's response to treatment are provided.
1 - 40 . (canceled)
41 . A method comprising:
(a) performing an immunological assay to obtain a first measured level for each of at least two inflammatory markers, at least two HPA axis markers, and at least two metabolic markers present in a first biological sample obtained from a mammal having a neuropsychiatric disease prior to administration of treatment for said disease, and using said first measured levels to calculate a first diagnostic disease score for said mammal, wherein said at least two inflammatory markers comprise a marker selected from the group consisting of alpha 1 antitrypsin, myeloperoxidase, soluble tumor necrosis factor α receptor (II), and apolipoprotein CIII, wherein said at least two HPA axis markers comprise a marker selected from the group consisting of epidermal growth factor and cortisol, and wherein said at least two metabolic markers comprise a marker selected from the group consisting of prolactin and resistin;
(b) performing said immunological assay to obtain a second measured level for each of said at least two inflammatory markers, at least two HPA axis markers, and at least two metabolic markers present in a second biological sample obtained from said mammal after administration of said treatment, and using said second measured levels to calculate a second diagnostic score for said mammal.
42 . The method of claim 41 , wherein said mammal is a human.
43 . The method of claim 41 , wherein said treatment is transcranial magnetic stimulation.
44 . The method of claim 41 , wherein said first diagnostic disease score is calculated using numerical values for the levels of at least two inflammatory markers, at least two HPA axis markers, at least two metabolic markers, and at least two neurotrophic markers present in said first biological sample.
45 . The method of claim 41 , wherein said second diagnostic disease score is calculated using numerical values for the levels of at least two inflammatory markers, at least two HPA axis markers, at least two metabolic markers, and at least two neurotrophic markers present in said second biological sample.
46 . The method of claim 41 , wherein said method comprises using a hypermap that comprises using a score for said levels of said inflammatory markers, a score for said levels of said at least two HPA axis markers, and a score for said levels of said at least two metabolic markers to compare said first and second diagnostic disease scores.
47 - 79 . (canceled)
80 . The method of claim 44 , wherein said at least two neurotrophic markers comprise brain-derived neurotrophic factor.
81 . The method of claim 45 , wherein said at least two neurotrophic markers comprise brain-derived neurotrophic factor.
82 . The method of claim 41 , further comprising adjusting said treatment of said mammal based at least in part on a comparison of said first diagnostic disease score to said second diagnostic disease score.
83 . The method of claim 82 , wherein said adjusting comprises adjusting the dose of said treatment.
84 . The method of claim 82 , wherein said comparison indicates a positive response to said treatment.
85 . The method of claim 82 , wherein said comparison indicates a failure to respond positively to said treatment.
86 . A method comprising:
(a) using binary logistic regression to develop first vector summaries based on first measured levels for at least two inflammatory markers, at least two HPA axis markers, at least two metabolic markers, and at least two neurotrophic markers present in a first biological sample obtained from a mammal with a neuropsychiatric disease, wherein said at least two inflammatory markers comprise a marker selected from the group consisting of alpha 1 antitrypsin, myeloperoxidase, soluble tumor necrosis factor α receptor (II), and apolipoprotein CIII, said at least two HPA axis markers comprise a marker selected from the group consisting of epidermal growth factor and cortisol, said at least two metabolic markers comprise a marker selected from the group consisting of prolactin and resistin, and said at least two neurotrophic markers comprise brain derived neurotrophic factor, wherein said first biological sample was obtained prior to administration of treatment for said neuropsychiatric disease;
(b) generating a hypermap with the first vector summaries from three of the four categories of inflammatory, HPA axis, metabolic, and neurotrophic markers;
(c) using binary logistic regression to develop second vector summaries based on second measured levels for said at least two inflammatory markers, at least two HPA axis markers, at least two metabolic markers, and at least two neurotrophic markers present in a second biological sample obtained from said mammal, wherein said second biological sample was obtained after administration of treatment for said neuropsychiatric disease;
(d) generating a second hypermap with said second vector summaries from said three of the four categories of inflammatory, HPA axis, metabolic, and neurotrophic markers; and
(e) comparing said first hypermap to said second hypermap to determine whether there is a positive or negative change in said subject's hyperspace pattern.
87 . A method comprising:
(a) performing an immunological assay to obtain a first measured level for each of at least two inflammatory markers, at least two HPA axis markers, at least two metabolic markers, and at least two neurotrophic markers present in a first biological sample obtained from a mammal with a neuropsychiatric disease, wherein said at least two inflammatory markers comprise a marker selected from the group consisting of alpha 1 antitrypsin, myeloperoxidase, soluble tumor necrosis factor α receptor (II), and apolipoprotein CIII, said at least two HPA axis markers comprise a marker selected from the group consisting of epidermal growth factor and cortisol, said at least two metabolic markers comprise a marker selected from the group consisting of prolactin and resistin, and said at least two neurotrophic markers comprise brain derived neurotrophic factor, wherein said first biological sample was obtained prior to administration of treatment for said neuropsychiatric disease;
(b) using binary logistic regression to develop first vector summaries based on said first measured levels for said at least two inflammatory markers, at least two HPA axis markers, and at least two metabolic markers;
(c) generating a hypermap with the first vector summaries from three of the four categories of inflammatory, HPA axis, metabolic, and neurotrophic markers;
(d) performing said immunological assay to obtain a second measured level for each of said at least two inflammatory markers, at least two HPA axis markers, and at least two metabolic markers present in a second biological sample obtained from said mammal after administration of said treatment;
(e) using binary logistic regression to develop second vector summaries based on said second measured levels for said at least two inflammatory markers, at least two HPA axis markers, at least two metabolic markers, and at least two neurotrophic markers;
(f) generating a second hypermap with said second vector summaries from said three of the four categories of inflammatory, HPA axis, metabolic, and neurotrophic markers; and
(g) comparing said first hypermap to said second hypermap to determine whether there is a positive or negative change in said subject's hyperspace pattern.